• Inicio
  • Resultados de la búsqueda
  • Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation.

Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation.

Journal of cancer research and clinical oncology (2014-05-06)
Lukas Peiffer, Simon Jonas Poll-Wolbeck, Hanna Flamme, Iris Gehrke, Michael Hallek, Karl-Anton Kreuzer
RESUMEN

The ontogenetic Wnt pathway shows almost no activity in adult tissues. In contrast, chronic lymphocytic leukemia (CLL) cells show constitutionally active Wnt signaling, which is associated with upregulated levels of pathway members such as Wnt3 and lymphoid enhancer-binding factor-1. Functionally, this results in increased resistance to apoptosis. We therefore assumed that targeting members of the pathway could reveal new therapeutic options for the treatment of CLL. Screening a Wnt compound library with 75 Wnt modulators via ATP assay revealed Trichostatin A as an outstanding substance with strong viability decreasing effects on CLL cells and little effect on healthy peripheral blood mononuclear cells (PBMCs). Further survival analysis was performed via fluorescence-activated cell sorting analysis. A maximum effect was achieved after 48 h with a wide therapeutic window in contrast to PBMCs (CLL cells: 0.253 µM, PBMCs: 145.22 µM). Trichostatin A induced caspases and acted via a dual mechanism to reveal histone and non-histone targets. Histone targets were displayed in deacetylation inhibition at DNA level, and non-histone targeting was demonstrated by elevated levels of Dickkopf-related protein 1 mRNA. Primary cells of patients with critical mutations such as TP53 or those who had already undergone extensive previous treatment responded well to the treatment. Moreover, the approved histone deacetylase (HDAC) inhibitor suberoylanilidehydroxamic acid (SAHA) was not as effective as Trichostatin A (Trichostatin A: 0.253 µM, SAHA: 7.88 µM). Combining Trichostatin A with established CLL drugs fludarabine or bendamustine showed an additive effect in vitro. Taken together, Trichostatin A appears to act via a dual anti-HDAC/Wnt mechanism with a high selectivity and efficacy in CLL and therefore warrants further investigation.

MATERIALES
Referencia del producto
Marca
Descripción del producto

SAFC
BIS-TRIS
Sigma-Aldrich
BIS-TRIS, ≥98.0% (titration)
Sigma-Aldrich
Trichostatin A, ≥98% (HPLC), from Streptomyces sp.
Sigma-Aldrich
SAHA, ≥98% (HPLC)
Sigma-Aldrich
Trichostatin A, Ready Made Solution, 5 mM in DMSO (0.2 μm-filtered), from Streptomyces sp.
Sigma-Aldrich
BIS-TRIS, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
BIS-TRIS, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
BIS-TRIS, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
SAFC
BIS-TRIS
Sigma-Aldrich
Monoclonal Anti-Rabbit IgG (γ-chain specific)−Alkaline Phosphatase antibody produced in mouse, clone RG-96, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-Rabbit IgG (γ-chain specific)–Peroxidase antibody, Mouse monoclonal, clone RG-96, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-Rabbit IgG (γ-chain specific) antibody produced in mouse, clone RG-96, ascites fluid
Sigma-Aldrich
Anti-Rabbit IgG, Native−Peroxidase antibody, Mouse monoclonal antibody produced in mouse, clone RabT-50, purified from hybridoma cell culture
Sigma-Aldrich
Anti-Rabbit IgG, Native antibody, Mouse monoclonal, clone RabT-50, purified from hybridoma cell culture
Sigma-Aldrich
Anti-Rabbit IgG (γ-chain specific)−Biotin antibody, Mouse monoclonal, clone RG-96, purified from hybridoma cell culture